BACKGROUND: Acute renal failure secondary to ischemia and reperfusion (I/R) injury poses a significant burden on both surgeons and patients. It carries a high morbidity and mortality rate and no specific treatment currently exists. Major causes of renal I/R injury include trauma, sepsis, hypoperfusion, and various surgical procedures. We have demonstrated that adrenomedullin (AM), a novel vasoactive peptide, combined with AM binding protein-1 (AMBP-1), which augments the activity of AM, is beneficial in various disease conditions. However, it remains unknown whether human AM/AMBP-1 provides any beneficial effects in renal I/R injury. The objective of our study therefore was to determine whether administration of human AM/AMBP-1 can prevent and/or minimize damage in a rat model of renal I/R injury. METHODS: Male adult rats were subjected to renal I/R injury by bilateral renal pedicle clamping with microvascular clips for 60 min followed by reperfusion. Human AM (12 microg/kg BW) and human AMBP-1 (40 microg/kg BW) or vehicle (52 microg/kg BW human albumin) were given intravenously over 30 min immediately following the clip removal (i.e., reperfusion). Rats were allowed to recover for 24 h post-treatment, and blood and renal tissue samples were collected. Plasma levels of AM were measured using a radioimmunoassay specific for rat AM. Plasma AMBP-1 was measured by Western analysis. Renal water content and serum levels of systemic markers of tissue injury were measured. Serum and renal TNF-alpha levels were also assessed. RESULTS: At 24 h after renal I/R injury, plasma levels of AM were significantly increased while plasma AMBP-1 was markedly decreased. Renal water content and systemic markers of tissue injury (e.g., creatinine, BUN, AST, and ALT) were significantly increased following renal I/R injury. Serum and renal TNF-alpha levels were also increased post injury. Administration of human AM/AMBP-1 decreased renal water content, and plasma levels of creatinine, BUN, AST, and ALT. Serum and renal TNF-alpha levels were also significantly decreased after AM/AMBP-1 treatment. CONCLUSION: Treatment with human AM/AMBP-1 in renal I/R injury significantly attenuated organ injury and the inflammatory response. Thus, human AM combined with human AMBP-1 may be developed as a novel treatment for patients with acute renal I/R injury. Copyright 2010 Elsevier Inc. All rights reserved.
BACKGROUND:Acute renal failure secondary to ischemia and reperfusion (I/R) injury poses a significant burden on both surgeons and patients. It carries a high morbidity and mortality rate and no specific treatment currently exists. Major causes of renal I/R injury include trauma, sepsis, hypoperfusion, and various surgical procedures. We have demonstrated that adrenomedullin (AM), a novel vasoactive peptide, combined with AM binding protein-1 (AMBP-1), which augments the activity of AM, is beneficial in various disease conditions. However, it remains unknown whether humanAM/AMBP-1 provides any beneficial effects in renal I/R injury. The objective of our study therefore was to determine whether administration of humanAM/AMBP-1 can prevent and/or minimize damage in a rat model of renal I/R injury. METHODS: Male adult rats were subjected to renal I/R injury by bilateral renal pedicle clamping with microvascular clips for 60 min followed by reperfusion. HumanAM (12 microg/kg BW) and humanAMBP-1 (40 microg/kg BW) or vehicle (52 microg/kg BW human albumin) were given intravenously over 30 min immediately following the clip removal (i.e., reperfusion). Rats were allowed to recover for 24 h post-treatment, and blood and renal tissue samples were collected. Plasma levels of AM were measured using a radioimmunoassay specific for ratAM. Plasma AMBP-1 was measured by Western analysis. Renal water content and serum levels of systemic markers of tissue injury were measured. Serum and renal TNF-alpha levels were also assessed. RESULTS: At 24 h after renal I/R injury, plasma levels of AM were significantly increased while plasma AMBP-1 was markedly decreased. Renal water content and systemic markers of tissue injury (e.g., creatinine, BUN, AST, and ALT) were significantly increased following renal I/R injury. Serum and renal TNF-alpha levels were also increased post injury. Administration of humanAM/AMBP-1decreased renal water content, and plasma levels of creatinine, BUN, AST, and ALT. Serum and renal TNF-alpha levels were also significantly decreased after AM/AMBP-1 treatment. CONCLUSION: Treatment with humanAM/AMBP-1 in renal I/R injury significantly attenuated organ injury and the inflammatory response. Thus, humanAM combined with humanAMBP-1 may be developed as a novel treatment for patients with acute renal I/R injury. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: R Pio; A Martinez; E J Unsworth; J A Kowalak; J A Bengoechea; P F Zipfel; T H Elsasser; F Cuttitta Journal: J Biol Chem Date: 2000-12-14 Impact factor: 5.157
Authors: Gilles Clermont; Christopher G Acker; Derek C Angus; Carl A Sirio; Michael R Pinsky; John P Johnson Journal: Kidney Int Date: 2002-09 Impact factor: 10.612
Authors: Philipp G H Metnitz; Claus G Krenn; Heinz Steltzer; Thomas Lang; Jürgen Ploder; Kurt Lenz; Jean-Roger Le Gall; Wilfred Druml Journal: Crit Care Med Date: 2002-09 Impact factor: 7.598
Authors: Mohamed H Zahran; Abdelaziz M Hussein; Nashwa Barakat; Amira Awadalla; Shery Khater; Ahmed Harraz; Ahmed A Shokeir Journal: Int Urol Nephrol Date: 2015-09-16 Impact factor: 2.370
Authors: Adam Khader; Weng-Lang Yang; Michael Kuncewitch; Jose M Prince; Philippe Marambaud; Jeffrey Nicastro; Gene F Coppa; Ping Wang Journal: J Surg Res Date: 2014-08-13 Impact factor: 2.192
Authors: Juan-Pablo Idrovo; Weng-Lang Yang; Asha Jacob; Michael A Ajakaiye; Cletus Cheyuo; Zhimin Wang; Jose M Prince; Jeffrey Nicastro; Gene F Coppa; Ping Wang Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240